# Atezolizumab

## Name 

阿替利珠单抗, Tecentriq（泰圣奇）

## Company

Roche

## MOA 

anti PD-l1

## Indication

 urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC).
 
## Remarks

 the first PD-L1 inhibitor approved by FDA

# Tiragolumab 

## Name

-

## MOA

anti-TIGIT

## Indication

NSCLC

## Remarks

The first a-TIGIT therapy. Therapy in combination with Tecentriq in Phase III.

# Bevacizumab

## Name

Avastin, 安维汀, 贝伐珠单抗

## Company

Roche

## MOA 

Antiangiogenic, targeting VEGF-A

## Indication 

Kidney, colon, rectum, lung, breast

## Remarks

The first antiangiogenic humanized mAb.
